Senior Scientist, Bioanalytical

Research Associate / Scientist

Attorney

Associate Director, Regulatory Affairs

Director/Sr. Director of Biostatistics

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Ansa Biotechnologies

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Ascidian Therapeutics

Ascribe Bioscience

Asher Biotherapeutics

Asimov

Larimar Therapeutics is developing therapies for rare genetic diseases that currently have no effective treatments. Genetic mutations can cause cells to have low levels of a protein which leads to disease. Using their proprietary protein replacement therapy platform, Larimar is developing disease modifying therapies that deliver missing proteins directly to cells that need it. Larimar’s lead candidate, CTI-1601, is currently being evaluated in Phase 1 clinical trials for Friedreich’s ataxia. Friedreich’s ataxia patients have low levels of endogenous Frataxin, a protein that functions in the mitochondria. CTI-1601 is a fusion protein that contains Frataxin and crosses the cell membrane into the cytoplasm. CTI-0601 also contains information to enter the mitochondria, where it is needed.

<p>Larimar Therapeutics is developing therapies for rare genetic diseases that currently have no effective treatments. Genetic mutations can cause cells to have low levels of a protein which leads to disease. Using their proprietary protein replacement therapy platform, Larimar is developing disease modifying therapies that deliver missing proteins directly to cells that need it. Larimar’s lead candidate, CTI-1601, is currently being evaluated in Phase 1 clinical trials for Friedreich’s ataxia. Friedreich’s ataxia patients have low levels of endogenous Frataxin, a protein that functions in the mitochondria. CTI-1601 is a fusion protein that contains Frataxin and crosses the cell membrane into the cytoplasm. CTI-0601 also contains information to enter the mitochondria, where it is needed.</p>


Larimar Therapeutics

Find a biotech startup job.